Literature DB >> 28470889

In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines.

K L Hippen1, R S O'Connor2, A M Lemire1, A Saha1, E A Hanse3, N C Tennis1, S C Merkel1, A Kelekar3, J L Riley4, B L Levine4, C H June4, L A Turka5, L S Kean6,7, M L MacMillan1, J S Miller8, J E Wagner1, D H Munn9, B R Blazar1.   

Abstract

Thymic regulatory T cells (tTregs) and induced regulatory T cells (iTregs) suppress murine acute graft-versus-host disease (GVHD). Previously, we demonstrated that the plasmacytoid dendritic cell indoleamine 2,3-dioxygenase (IDO) fosters the in vitro development of human iTregs via tryptophan depletion and kynurenine (Kyn) metabolites. We now show that stimulation of naïve CD4+ T cells in low tryptophan (low Trp) plus Kyn supports human iTreg generation. In vitro, low Trp + Kyn iTregs and tTregs potently suppress T effector cell proliferation equivalently but are phenotypically distinct. Compared with tTregs or T effector cells, bioenergetics profiling reveals that low Trp + Kyn iTregs have increased basal glycolysis and oxidative phosphorylation and use glutaminolysis as an energy source. Low Trp + Kyn iTreg viability was reliant on interleukin (IL)-2 in vitro. Although in vivo IL-2 administration increased low Trp + Kyn iTreg persistence on adoptive transfer into immunodeficient mice given peripheral blood mononuclear cells to induce GVHD, IL-2-supported iTregs did not improve recipient survival. We conclude that low Trp + Kyn create suppressive iTregs that have high metabolic needs that will need to be addressed before clinical translation.
© 2017 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  T cell biology; basic (laboratory) research/science; bone marrow/hematopoietic stem cell transplantation; graft-versus-host disease (GVHD); immune regulation; immunosuppression/immune modulation; tolerance: clinical; translational research/science; xenotransplantation

Mesh:

Substances:

Year:  2017        PMID: 28470889      PMCID: PMC5671378          DOI: 10.1111/ajt.14338

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  51 in total

1.  Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction.

Authors:  David R Wise; Ralph J DeBerardinis; Anthony Mancuso; Nabil Sayed; Xiao-Yong Zhang; Harla K Pfeiffer; Ilana Nissim; Evgueni Daikhin; Marc Yudkoff; Steven B McMahon; Craig B Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-24       Impact factor: 11.205

2.  Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

Authors:  Alexander J Muller; James B DuHadaway; P Scott Donover; Erika Sutanto-Ward; George C Prendergast
Journal:  Nat Med       Date:  2005-02-13       Impact factor: 53.440

3.  From Krebs to clinic: glutamine metabolism to cancer therapy.

Authors:  Brian J Altman; Zachary E Stine; Chi V Dang
Journal:  Nat Rev Cancer       Date:  2016-11-11       Impact factor: 60.716

4.  Prevention of allogeneic fetal rejection by tryptophan catabolism.

Authors:  D H Munn; M Zhou; J T Attwood; I Bondarev; S J Conway; B Marshall; C Brown; A L Mellor
Journal:  Science       Date:  1998-08-21       Impact factor: 47.728

5.  An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos.

Authors:  Madhav D Sharma; Lei Huang; Jeong-Hyeon Choi; Eun-Joon Lee; James M Wilson; Henrique Lemos; Fan Pan; Bruce R Blazar; Drew M Pardoll; Andrew L Mellor; Huidong Shi; David H Munn
Journal:  Immunity       Date:  2013-05-16       Impact factor: 31.745

6.  Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality.

Authors:  Lisa K Jasperson; Christoph Bucher; Angela Panoskaltsis-Mortari; Andrew L Mellor; David H Munn; Bruce R Blazar
Journal:  Blood       Date:  2009-10-14       Impact factor: 22.113

Review 7.  Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage?

Authors:  Jochen Huehn; Julia K Polansky; Alf Hamann
Journal:  Nat Rev Immunol       Date:  2009-02       Impact factor: 53.106

Review 8.  Advances in graft-versus-host disease biology and therapy.

Authors:  Bruce R Blazar; William J Murphy; Mehrdad Abedi
Journal:  Nat Rev Immunol       Date:  2012-05-11       Impact factor: 53.106

9.  IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan.

Authors:  Richard Metz; Sonja Rust; James B Duhadaway; Mario R Mautino; David H Munn; Nicholas N Vahanian; Charles J Link; George C Prendergast
Journal:  Oncoimmunology       Date:  2012-12-01       Impact factor: 8.110

10.  Inhibition of indoleamine 2,3-dioxygenase-mediated tryptophan catabolism accelerates collagen-induced arthritis in mice.

Authors:  Sándor Szántó; Tamás Koreny; Katalin Mikecz; Tibor T Glant; Zoltán Szekanecz; John Varga
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

View more
  14 in total

Review 1.  Methods to manufacture regulatory T cells for cell therapy.

Authors:  K N MacDonald; J M Piret; M K Levings
Journal:  Clin Exp Immunol       Date:  2019-04-15       Impact factor: 4.330

Review 2.  Therapeutic use of regulatory T cells for graft-versus-host disease.

Authors:  Shlomo Elias; Alexander Y Rudensky
Journal:  Br J Haematol       Date:  2019-08-16       Impact factor: 6.998

3.  Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37.

Authors:  Dhifaf Sarhan; Keli L Hippen; Amanda Lemire; Skyler Hying; Xianghua Luo; Todd Lenvik; Julie Curtsinger; Zachary Davis; Bin Zhang; Sarah Cooley; Frank Cichocki; Bruce R Blazar; Jeffrey S Miller
Journal:  Cancer Immunol Res       Date:  2018-05-21       Impact factor: 11.151

4.  Metabolic reprogramming augments potency of human pSTAT3-inhibited iTregs to suppress alloreactivity.

Authors:  Kelly Walton; Mario R Fernandez; Elizabeth M Sagatys; Jordan Reff; Jongphil Kim; Marie Catherine Lee; John V Kiluk; Jane Yuet Ching Hui; David McKenna; Meghan Hupp; Colleen Forster; Michael A Linden; Nicholas J Lawrence; Harshani R Lawrence; Joseph Pidala; Steven Z Pavletic; Bruce R Blazar; Said M Sebti; John L Cleveland; Claudio Anasetti; Brian C Betts
Journal:  JCI Insight       Date:  2020-05-07

5.  IL-2 enhances ex vivo-expanded regulatory T-cell persistence after adoptive transfer.

Authors:  Scott N Furlan; Karnail Singh; Christina Lopez; Victor Tkachev; Daniel Joel Hunt; James Hibbard; Kayla M Betz; Bruce R Blazar; Cole Trapnell; Leslie S Kean
Journal:  Blood Adv       Date:  2020-04-28

Review 6.  Therapeutic Liposomal Vaccines for Dendritic Cell Activation or Tolerance.

Authors:  Noémi Anna Nagy; Aram M de Haas; Teunis B H Geijtenbeek; Ronald van Ree; Sander W Tas; Yvette van Kooyk; Esther C de Jong
Journal:  Front Immunol       Date:  2021-05-13       Impact factor: 7.561

7.  Differential Regulation of Human Treg and Th17 Cells by Fatty Acid Synthesis and Glycolysis.

Authors:  Deborah Cluxton; Andreea Petrasca; Barry Moran; Jean M Fletcher
Journal:  Front Immunol       Date:  2019-02-04       Impact factor: 7.561

Review 8.  Distinct Regulatory and Effector T Cell Metabolic Demands during Graft-Versus-Host Disease.

Authors:  Keli L Hippen; Ethan G Aguilar; Stephanie Y Rhee; Sara Bolivar-Wagers; Bruce R Blazar
Journal:  Trends Immunol       Date:  2019-11-30       Impact factor: 16.687

9.  TIGIT+ iTregs elicited by human regulatory macrophages control T cell immunity.

Authors:  Paloma Riquelme; Jan Haarer; Anja Kammler; Lisa Walter; Stefan Tomiuk; Norbert Ahrens; Anja K Wege; Ivan Goecze; Daniel Zecher; Bernhard Banas; Rainer Spang; Fred Fändrich; Manfred B Lutz; Birgit Sawitzki; Hans J Schlitt; Jordi Ochando; Edward K Geissler; James A Hutchinson
Journal:  Nat Commun       Date:  2018-07-20       Impact factor: 14.919

10.  The lineage stability and suppressive program of regulatory T cells require protein O-GlcNAcylation.

Authors:  Bing Liu; Oscar C Salgado; Sangya Singh; Keli L Hippen; Jason C Maynard; Alma L Burlingame; Lauren E Ball; Bruce R Blazar; Michael A Farrar; Kristin A Hogquist; Hai-Bin Ruan
Journal:  Nat Commun       Date:  2019-01-21       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.